Tag: Cancer Therapy
-
New Insights into Why Some Breast Cancers Resist Antibody-Drug Conjugates (ADCs) Therapy
Understanding ADCs and Why They Matter in Breast Cancer Antibody‑drug conjugates (ADCs) are a cutting‑edge class of cancer therapies designed to target malignant cells with precision. By pairing a cancer‑specific antibody with a potent cytotoxic drug, ADCs aim to destroy tumor cells while limiting damage to healthy tissue. In breast cancer, ADCs have shown promise,…
-
Why Some Breast Cancers Resist Antibody Drug Conjugates: New Mayo Clinic Insights
Understanding the Challenge: Breast Cancer and Antibody Drug Conjugates Antibody drug conjugates (ADCs) represent a promising class of targeted cancer therapies. They couple a cancer-seeking antibody with a potent cytotoxic drug, delivering treatment directly to tumor cells while aiming to spare healthy tissue. In breast cancer, these therapies have shown notable potential, especially for tumors…
-
HIV Research: A Catalyst for Breakthroughs Across Medicine
The Enduring Impact of HIV Research HIV/AIDS research has become more than a focused effort against a single disease. Over the past four decades, U.S.-funded HIV research has advanced science in ways that touch immunology, cancer therapy, vaccines, and global health at large. A recent Nature Medicine commentary by leading researchers highlights how this sustained…
-
Changing the Narrative: How Calgary’s iSARP Is Redefining Sarcoma Therapy
Changing the Narrative in Calgary’s Medical Landscape When Dr. Michael Monument returned to his hometown of Calgary in 2014 after a fellowship at the University of Utah, colleagues warned him that the city might not be the best place to pursue sarcoma research. Sarcoma, a relatively rare family of bone and soft tissue tumors that…
-
TIGIT Immune Checkpoint Promotes Tissue Healing and Regeneration
Overview: A new role for an immune checkpoint Immune checkpoint inhibitors have transformed cancer therapy by releasing the brakes on the immune system. A surprising new finding from researchers at the University of Zurich (UZH) reveals that one such brake, TIGIT, does more than help tumor-fighting immune cells—it also promotes tissue healing. This discovery could…
-
CancerVax Precision Therapy Demonstrates Liver-Sparing Potential in In-Vitro Tests
Breakthrough in Precision Cancer Therapy: Liver-Sparing in Early Studies Lehi, Utah — CancerVax, Inc., a pre-clinical biotechnology company, announced today that recent in-vitro studies demonstrate a significant reduction in liver toxicity for its universal cancer treatment platform. The findings address a long-standing challenge in oncology: protecting healthy liver tissue while delivering effective cancer-killing therapy. If…
-
Genomic Insights Offer Hope for Tailored Osteosarcoma Therapies
New genomic study highlights epigenetic drivers of osteosarcoma An international team led by Livia Garzia, PhD, Nada Jabado, MD, PhD, and Claudia Kleinman, PhD, has unveiled important epigenetic features in osteosarcoma, offering fresh directions for prognosis and treatment. The findings, published in Nature Communications, illuminate how epigenetic regulation shapes this aggressive bone cancer that primarily…
-
Nobel Prize in Medicine Honors Immune System’s Regulatory Guards
The Nobel Prize in Medicine recognizes a trio whose work uncovered the immune system’s “security guards.” The 2024 Nobel Prize in Physiology or Medicine was awarded to Mary Brunkow and Fred Ramsdell of the United States and Shimon Sakaguchi of Japan for identifying regulatory T-cells, the immune system’s key regulators that keep immune responses in…
-
Nobel Prize in Medicine Honors Trio Uncovering Immune System’s ‘Security Guards’
Nobel Prize in Medicine Awards Recognize Immune System Regulators The Nobel Prize in Medicine was awarded to a US-Japanese trio for groundbreaking work on how the immune system keeps itself in check. Mary Brunkow and Fred Ramsdell, both based in the United States, and Shimon Sakaguchi of Japan’s Osaka University were celebrated for identifying the…
-
LncRNA-MAPK Interplay in Breast Cancer: Unlocking New Paths for Therapy
Introduction: Why lncRNAs and MAPK Matter in Breast Cancer Breast cancer is driven by a network of signaling pathways that control cell growth, survival, and metastasis. Among these, the mitogen-activated protein kinase (MAPK) cascades—comprising ERK, JNK, and p38—translate extracellular cues into precise cellular responses. In recent years, long non-coding RNAs (lncRNAs) have emerged as powerful…